Logo image of EYEN

EYENOVIA INC (EYEN) Stock Fundamental Analysis

USA - NASDAQ:EYEN - US30234E2037 - Common Stock

15.82 USD
+5.26 (+49.81%)
Last: 7/2/2025, 8:00:02 PM
15.9 USD
+0.08 (+0.51%)
After Hours: 7/2/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, EYEN scores 1 out of 10 in our fundamental rating. EYEN was compared to 196 industry peers in the Pharmaceuticals industry. EYEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, EYEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EYEN had negative earnings in the past year.
EYEN had a negative operating cash flow in the past year.
In the past 5 years EYEN always reported negative net income.
EYEN had a negative operating cash flow in each of the past 5 years.
EYEN Yearly Net Income VS EBIT VS OCF VS FCFEYEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -708.22%, EYEN is doing worse than 96.91% of the companies in the same industry.
Industry RankSector Rank
ROA -708.22%
ROE N/A
ROIC N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EYEN Yearly ROA, ROE, ROICEYEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EYEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EYEN Yearly Profit, Operating, Gross MarginsEYEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K -600K

More info and screens

0

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
EYEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EYEN has been increased compared to 5 years ago.
The debt/assets ratio for EYEN is higher compared to a year ago.
EYEN Yearly Shares OutstandingEYEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
EYEN Yearly Total Debt VS Total AssetsEYEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -62.11, we must say that EYEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -62.11, EYEN is not doing good in the industry: 93.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -62.11
ROIC/WACCN/A
WACC10.96%
EYEN Yearly LT Debt VS Equity VS FCFEYEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

EYEN has a Current Ratio of 0.34. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
EYEN has a Current ratio of 0.34. This is amonst the worse of the industry: EYEN underperforms 94.85% of its industry peers.
EYEN has a Quick Ratio of 0.34. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
EYEN's Quick ratio of 0.34 is on the low side compared to the rest of the industry. EYEN is outperformed by 93.81% of its industry peers.
Industry RankSector Rank
Current Ratio 0.34
Quick Ratio 0.34
EYEN Yearly Current Assets VS Current LiabilitesEYEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

EYEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.07%, which is quite impressive.
The Revenue has grown by 781.58% in the past year. This is a very strong growth!
EYEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -84.00% yearly.
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%

3.2 Future

Based on estimates for the next years, EYEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.19% on average per year.
Based on estimates for the next years, EYEN will show a very strong growth in Revenue. The Revenue will grow by 135.99% on average per year.
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EYEN Yearly Revenue VS EstimatesEYEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
EYEN Yearly EPS VS EstimatesEYEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYEN. In the last year negative earnings were reported.
Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYEN Price Earnings VS Forward Price EarningsEYEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYEN Per share dataEYEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as EYEN's earnings are expected to grow with 20.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.63%
EPS Next 3Y20.36%

More info and screens

0

5. Dividend

5.1 Amount

EYEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYENOVIA INC

NASDAQ:EYEN (7/2/2025, 8:00:02 PM)

After market: 15.9 +0.08 (+0.51%)

15.82

+5.26 (+49.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-19 2025-05-19/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners9.67%
Inst Owner Change0%
Ins Owners0.74%
Ins Owner Change0.52%
Market Cap80.68M
Analysts47.5
Price Target163.2 (931.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.5%
Min EPS beat(2)5.64%
Max EPS beat(2)83.35%
EPS beat(4)3
Avg EPS beat(4)17.71%
Min EPS beat(4)-37.25%
Max EPS beat(4)83.35%
EPS beat(8)5
Avg EPS beat(8)6.62%
EPS beat(12)7
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)16.18%
Revenue beat(2)0
Avg Revenue beat(2)-96.53%
Min Revenue beat(2)-96.75%
Max Revenue beat(2)-96.32%
Revenue beat(4)0
Avg Revenue beat(4)-97.36%
Min Revenue beat(4)-98.79%
Max Revenue beat(4)-96.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1204.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-34.16
EYN/A
EPS(NY)-26.52
Fwd EYN/A
FCF(TTM)-4.85
FCFYN/A
OCF(TTM)-4.84
OCFYN/A
SpS0.01
BVpS-1.9
TBVpS-1.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -708.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.34
Quick Ratio 0.34
Altman-Z -62.11
F-Score3
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)219.51%
Cap/Depr(5y)330.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.59%
EBIT Next 3Y54.61%
EBIT Next 5Y39.01%
FCF growth 1Y2.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.27%
OCF growth 3YN/A
OCF growth 5YN/A